Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 3, 2011, Pages 668-678

  Simons, David ^a   Grieb, Gerrit ^a   Hristov, Mihail ^a   Pallua, Norbert ^a   Weber, Christian ^a   Bernhagen, Jürgen ^a   Steffens, Guy ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Endothelial cell (EC); Endothelial progenitor cells (EPCs); Macrophage migration inhibitory factor (MIF); Stromal cell derived factor 1 (SDF 1 CXCL12)

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; GLIBENCLAMIDE; MACROPHAGE MIGRATION INHIBITION FACTOR; OXYGEN; RECOMBINANT PROTEIN;

ARTICLE; CELL CULTURE; CELL HYPOXIA; CELL MOTION; CELL SURVIVAL; CHEMOTAXIS; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; METABOLISM; STEM CELL; TIME;

CELL HYPOXIA; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; CHEMOTAXIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYBURIDE; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; OXYGEN; RECEPTORS, CXCR4; RECOMBINANT PROTEINS; STEM CELLS; TIME FACTORS;

EID: 79953295567     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01041.x     Document Type: Article

References (44)

1. Bernhagen J, Calandra T, Bucala R. Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. J Mol Med. 1998; 76: 151-61.
2. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003; 3: 791-800.
3. Morand EF, Leech M, Bernhagen J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov. 2006; 5: 399-410.
4. Zernecke A, Bernhagen J, Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation. 2008; 117: 1594-602.
5. Bernhagen J, Krohn R, Lue H et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007; 13: 587-96.
6. Weber C, Kraemer S, Drechsler M, et al. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci USA. 2008; 105: 16278-83.
7. Beider K, Abraham M, Peled A. Chemokines and chemokine receptors in stem cell circulation. Front Biosci. 2008; 13: 6820-33.
8. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med. 1998; 338: 436-45.
9. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006; 354: 610-21.
10. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10: 858-64.
11. Yu JX, Huang XF, Lv WM, et al. Combination of stromal-derived factor-1alpha and vascular endothelial growth factor gene-modified endothelial progenitor cells is more effective for ischemic neovascularization. J Vasc Surg. 2009; 50: 608-16.
12. Hristov M, Zernecke A, Liehn EA, et al. Regulation of endothelial progenitor cell homing after arterial injury. Thromb Haemost. 2007; 98: 274-7.
13. Jujo K, Ii M, Losordo DW. Endothelial progenitor cells in neovascularization of infarcted myocardium. J Mol Cell Cardiol. 2008; 45: 530-44.
14. Real C, Caiado F, Dias S. Endothelial progenitors in vascular repair and angiogenesis: how many are needed and what to do Cardiovasc Hematol Disord Drug Targets. 2008; 8: 185-93.
15. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med. 2004; 8: 498-508.
16. Hristov M, Weber C. Endothelial progenitor cells in vascular repair and remodeling. Pharmacol Res. 2008; 58: 148-51.
17. Hristov M, Weber C. Progenitor cell trafficking in the vascular wall. J Thromb Haemost. 2009; 7: 31-4.
18. Pearson JD. Endothelial progenitor cells - hype or hope J Thromb Haemost. 2009; 7: 255-62.
19. Timmermans F, Plum J, Yoder MC, et al. Endothelial progenitor cells: identity defined J Cell Mol Med. 2009; 13: 87-102.
20. Sieveking DP, Buckle A, Celermajer DS, et al. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol. 2008; 51: 660-8.
21. Kupatt C, Horstkotte J, Vlastos GA, et al. Embryonic endothelial progenitor cells expressing a broad range of proangiogenic and remodeling factors enhance vascularization and tissue recovery in acute and chronic ischemia. FASEB J. 2005; 19: 1576-8.
22. Ceradini DJ, Gurtner GC. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med. 2005; 15: 57-63.
23. Baugh JA, Gantier M, Li L, et al. Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem Biophys Res Commun. 2006; 347: 895-903.
24. Flieger O, Engling A, Bucala R, et al. Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett. 2003; 551: 78-86.
25. Merk M, Baugh J, Zierow S, et al. The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol. 2009; 182: 6896-906.
26. Nickel W, Rabouille C. Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol. 2009; 10: 148-55.
27. Jaffe EA, Nachman RL, Becker CG, et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973; 52: 2745-56.
28. Grieb G, Groger A, Piatkowski A, et al. Tissue substitutes with improved angiogenic capabilities: an in vitro investigation with endothelial cells and endothelial progenitor cells. Cells Tissues Organs. 2010; 191: 96-104.
29. Nishihira J, Koyama Y, Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine. 1998; 10: 199-205.
30. Okamoto T, Atsumi T, Shimizu C, et al. The potential role of macrophage migration inhibitory factor on the migration of vascular smooth muscle cells. J Atheroscler Thromb. 2008; 15: 13-9.
31. Burger-Kentischer A, Goebel H, Seiler R, et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation. 2002; 105: 1561-6.
32. Schmeisser A, Marquetant R, Illmer T, et al. The expression of macrophage migration inhibitory factor 1alpha (MIF 1alpha) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability. Atherosclerosis. 2005; 178: 83-94.
33. Schober A, Bernhagen J, Thiele M, et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation. 2004; 109: 380-5.
34. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch. 2007; 455: 479-92.
35. Larsen M, Tazzyman S, Lund EL, et al. Hypoxia-induced secretion of macrophage migration-inhibitory factor from MCF-7 breast cancer cells is regulated in a hypoxia-inducible factor-independent manner. Cancer Lett. 2008; 265: 239-49.
36. Miller EJ, Li J, Leng L, et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature. 2008; 451: 578-82.
37. Jian Z, Li JB, Ma RY, et al. Increase of macrophage migration inhibitory factor (MIF) expression in cardiomyocytes during chronic hypoxia. Clin Chim Acta. 2009; 405: 132-8.
38. Wang L, Zis O, Ma G, et al. Upregulation of macrophage migration inhibitory factor gene expression in stroke. Stroke. 2009; 40: 973-6.
39. Kleemann R, Hausser A, Geiger G, et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature. 2000; 408: 211-6.
40. Lue H, Kapurniotu A, Fingerle-Rowson G et al. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal. 2006; 18: 688-703.
41. Berndt K, Kim M, Meinhardt A, et al. Macrophage migration inhibitory factor does not modulate co-activation of androgen receptor by Jab1/CSN5. Mol Cell Biochem. 2008; 307: 265-71.
42. Koch N, Moldenhauer G, Hofmann WJ, et al. Rapid intracellular pathway gives rise to cell surface expression of the MHC class II-associated invariant chain (CD74). J Immunol. 1991; 147: 2643-51.
43. Shim H, Lau SK, Devi S, et al. Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun. 2006; 346: 252-8.
44. Rubartelli A, Cozzolino F, Talio M, et al. A novel secretory pathway for interleukin-1β, a protein lacking a signal sequence. EMBO J. 1990; 9: 1503-10.